As Congress returns, lawmakers rush to detail drug-pricing agendas
(By Lev Facher for STAT) WASHINGTON — Chuck Grassley wasted little time this week in unveiling his drug-pricing agenda, attaching his
Read moreLegislative Update
Medicaid ‘Buy-In’ Could Be a New Health Care Option for the Uninsured
(By Michael Ollove for Stateline, an initiative of The Pew Charitable Trusts) Even as calls for “Medicare for All” grow
Read moreHow PhRMA finally lost: the inside story of the group’s biggest lobbying failure in years
(By Nicholas Florko for STAT) WASHINGTON —The drug industry’s storied lobbying group isn’t accustomed to bad news — and with
Read moreJudge blocks Trump administration cuts to 340B hospital drug-discount program
(By Ike Swetlitz for STAT) A federal judge has blocked a Trump administration policy that reduces payments to hospitals under
Read more3 state legislative battles to watch in 2019
(By Lev Facher for STAT) WASHINGTON — Drug pricing is on the agenda here in 2019. But with Republicans controlling
Read morePowerful Democrat wants Pfizer to explain price hikes for Lyrica, its nerve pain drug
(By Nicholas Florko for STAT) WASHINGTON — A powerful Senate Democrat is asking Pfizer to explain why it hiked the
Read moreBipartisan action on surprise medical bills expected next year, senator says
(By Kelly Gooch for Becker’s Hospital Review) U.S. Sen. Bill Cassidy, R-La., said federal lawmakers on both sides of the aisle
Read moreSen. Cory Booker Calls For More Transparency In Medicaid Drug Decisions
(By Liz Whyte for NPR and The Center for Public Integrity) Sen. Cory Booker, D-N.J., says he will introduce federal
Read moreRed Tape Relief effort to roll back Medicare regulations on hospitals
On Tuesday, Republicans on the House Ways and Means Committee introduced seven bills to roll back Medicare regulations on hospitals.
Read moreThe long-delayed 340B final rule is out
The rule for the 340B drug discount program, which would set price ceilings and monetary penalties, will begin of next
Read more